Pharma & Biotech VC & Investment News
Biotechnology
French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical activity across both solid and blood cancers. 12 June 2025
Today's issue
Refine Search
Biotechnology
US biotech Artis BioSolutions has officially launched with the acquisition of Landmark Bio, a translational development and manufacturing group formed through an alliance of academic and industry stakeholders. 2 April 2025
Biotechnology
US healthcare giant Johnson & Johnson’s venture capital arm has made its first investment in South Korea, leading a $20 million series B financing round for Prazer Therapeutics, a biotech focused on targeted protein degradation. 2 April 2025
Biotechnology
US biotech AIRNA has raised $155 million in series B funding to advance its lead RNA-editing therapy into human trials and expand its pipeline of genetic medicines targeting both rare and common diseases. 1 April 2025
Pharmaceutical
UK-based AI-first development company Isomorphic Labs revealed that it has raised $600 Million in its first external funding round. 1 April 2025
Biotechnology
US genomics firm Galatea Bio has raised $25 million in funding to expand its global biobank and accelerate the development of AI-powered tools for drug discovery and disease risk prediction, with a particular focus on populations historically left out of genomic research. 28 March 2025
Pharmaceutical
UK-based specialty pharma Kelso Pharma, which is backed by private equity investor Apposite Capital, announced that it has secured over £140 million ($180 million) of acquisition funding. 27 March 2025
Biotechnology
San Francisco-based epigenetic editing company Epicrispr Biotechnologies has secured $68 million in the first close of its Series B financing. 27 March 2025
Biotechnology
Polygenic diseases company Character Biosciences has announced an oversubscribed $93 million Series B financing round to accelerate the advancement of its pipeline of precision therapies to treat degenerative eye diseases, starting with age-related macular degeneration (AMD). 26 March 2025
Biotechnology
Newly-launched Hillstar Bio, a US biotech developing precision immunology therapies for autoimmune diseases, has announced the successful closing of a $67 million Series A financing round. 25 March 2025
Pharmaceutical
US biotech Tempero Bio has raised $70 million in a series B financing and brought in a new chief medical officer as it pushes ahead with clinical development of its lead candidate, TMP-301, for substance use disorders. 25 March 2025
Biotechnology
Augustine Therapeutics, a Belgian biotech developing therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, has successfully completed its Series A financing round. 24 March 2025
Biotechnology
Sinovac Biotech, a China-based biopharmaceutical company specializing in vaccine development, has been urged by shareholder Heng Ren Partners to distribute $8.9 billion in cash reserves to shareholders and to resume trading of its shares on Nasdaq. 24 March 2025
Biotechnology
US biotech GRO Biosciences is weighing the way forward for its lead gout program following a quiet restructuring that saw a reduction in research staff and key leadership changes. 21 March 2025
Biotechnology
Ampersand Biomedicines today announced it has secured $65 million in Series B funding from investors including Ampersand’s founder, the bioplatform company builder Flagship Pioneering, as well as pharma major Eli Lilly and several additional new investors. 19 March 2025
Biotechnology
US genetic medicin0es firm Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS). 19 March 2025
Biotechnology
RegCell, a Japanese-founded biotechnology company, has announced the closing of an oversubscribed seed round and its transition to a USA-based company, based in Emeryville, California. 19 March 2025
Biotechnology
European life sciences venture capital firm Sofinnova Partners and French cancer research hospital Gustave Roussy have announced the creation of their first biotech company. 18 March 2025
Biotechnology
Forth Therapeutics, a UK biotechnology company focused on precision treatments for fibrosis, has launched with support from European venture capital firm Sofinnova Partners and Old College Capital, the University of Edinburgh’s investment arm. 18 March 2025
Pharmaceutical
Seattle, USA-based biotech Curevo Vaccine, which is developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles. 18 March 2025
Biotechnology
California-based Latigo Biotherapeutics, a biotech developing non-opioid pain treatments, has closed $150 million in a Series B financing. 17 March 2025
Pharmaceutical
Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership shake-up timed with a fresh $25 million financing round and a push to commercialize its lead eye implant therapy in the USA. 19 June 2025
Pharmaceutical
US biotech Actio Biosciences has raised $66 million in a series B round topport its pipeline of genetically targeted therapies, with new funding led by Regeneron Ventures and repeat backing from Deerfield Management. 19 June 2025
Biotechnology
Chinese biotech start-up BioTroy Therapeutics has raised over 200 million renminbi ($28 million) in series A financing to advance clinical trials for its experimental immunotherapy targeting CD3L1, a novel immune checkpoint aimed at tough-to-treat tumors. The company also plans to expand its early-stage pipeline and grow its Shanghai-based R&D team. 18 June 2025
Biotechnology
EY today released its 35th annual Biotech Beyond Borders Report. This finds that the biopharma industry is currently at an inflection point – grappling with a unique environment of macroeconomic uncertainty and constrained access to capital, including high interest rates, inflation, shifting regulatory policies and tariff turmoil. 18 June 2025
Pharmaceutical
Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric diseases, today launched from stealth having raised a total of $140 million (£107 million) in the last nine months. 18 June 2025
Biotechnology
French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical activity across both solid and blood cancers. 12 June 2025
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Biotechnology
Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. 11 June 2025
Pharmaceutical
China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its first-in-class, ultra-long-acting GLP-1 receptor agonist for type 2 diabetes, alongside a move to go public on the Hong Kong Stock Exchange. 11 June 2025
Biotechnology
Spanish biotech SpliceBio has secured $135 million in series B financing to accelerate development of its experimental gene therapy, SB-007, for Stargardt disease and expand its broader pipeline of genetic medicines. 11 June 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of the company post the placement. The shares were placed at HK$331.8 per share, raising net proceeds of around US$250 million. 6 June 2025
Pharmaceutical
US biotech Trevi Therapeutics has raised around $115 million in a public stock offering, giving it fresh momentum to continue developing its investigational therapy Haduvio (nalbuphine) for chronic cough. 6 June 2025
Biotechnology
Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the sale process, following an eleventh hour bid from company co-founder Anne Wojcicki. 6 June 2025
Biotechnology
San Jose, USA-based biotech Allay Therapeutics today announced the completion of a $57.5 million Series D financing round with leading global investors. 5 June 2025
Pharmaceutical
Sweden’s Karolinska Development today revealed that its portfolio company OssDsign has carried out a directed share issue through an accelerated book-building procedure that brought the company approximately 158 million kronor ($16.5 million). 4 June 2025
Pharmaceutical
Philadelphia-based biotech Vivodyne has raised $40 million in series A funding to advance its fully robotic, AI-powered platform that tests drug candidates on lab-grown human tissues. 30 May 2025
Biotechnology
Vima Therapeutics, a Cambridge, USA-based clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing. 30 May 2025
Biotechnology
US biotech Moderna has reported encouraging early-stage results from a trial of its experimental vaccine for avian influenza, just as a significant federal funding agreement was unexpectedly withdrawn. 29 May 2025
Pharmaceutical
US biotech Syndeio Biosciences has launched with over $90 million in funding and a pipeline of synapse-targeting neurotherapies aimed at treating major depressive disorder, Alzheimer’s disease, and other central nervous system (CNS) conditions. 27 May 2025
Pharmaceutical
Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced a debt financing agreement for up to $262.5 million from funds managed by Blue Owl Capital. 27 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze